Home LiteratureArticle Details
PMID: 12941881 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S. Review

Ebola virus pathogenesis: implications for vaccines and therapies.

Journal of virology ·Vol. 77 ·No. 18 ·2003-09-00 ·Pages 9733-7

Sullivan N, Yang ZY, Nabel GJ

Abstract

暂无摘要

MeSH Terms
Animals Disease Progression Ebolavirus/classification,immunology,pathogenicity Hemorrhagic Fever, Ebola/immunology,therapy Humans Viral Vaccines/immunology
Chemicals
Viral Vaccines
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Sullivan Nancy
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, MD 20892-3005, USA.
Yang Zhi-Yong
Nabel Gary J
References (50)
50 references, click to expand
  1. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.
    Nat Med. 1998 Nov;4(11):1302-7 PMID: 9809555
  2. Development of a preventive vaccine for Ebola virus infection in primates.
    Nature. 2000 Nov 30;408(6812):605-9 PMID: 11117750
  3. Filovirus diseases.
    Curr Top Microbiol Immunol. 1999;235:85-95 PMID: 9893380
  4. A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. Commission de Lutte contre les Epidémies à Kikwit.
    J Infect Dis. 1999 Feb;179 Suppl 1:S36-47 PMID: 9988163
  5. Histopathological and immunohistochemical studies of lesions associated with Ebola virus in a naturally infected chimpanzee.
    J Infect Dis. 1999 Feb;179 Suppl 1:S54-9 PMID: 9988165
  6. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection.
    J Infect Dis. 1999 Feb;179 Suppl 1:S188-91 PMID: 9988183
  7. Pathogenesis of experimental Ebola virus infection in guinea pigs.
    J Infect Dis. 1999 Feb;179 Suppl 1:S203-17 PMID: 9988186
  8. Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A resolution.
    Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2662-7 PMID: 10077567
  9. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients.
    Nat Med. 1999 Apr;5(4):423-6 PMID: 10202932
  10. Ebola virus secretory glycoprotein (sGP) diminishes Fc gamma RIIIB-to-CR3 proximity on neutrophils.
    J Immunol. 2000 Jan 15;164(2):953-8 PMID: 10623844
  11. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity.
    Science. 2001 Mar 9;291(5510):1965-9 PMID: 11239157
  12. Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication.
    J Virol. 2001 May;75(10):4649-54 PMID: 11312335
  13. Folate receptor-alpha is a cofactor for cellular entry by Marburg and Ebola viruses.
    Cell. 2001 Jul 13;106(1):117-26 PMID: 11461707
  14. Infection and activation of monocytes by Marburg and Ebola viruses.
    J Virol. 2001 Nov;75(22):11025-33 PMID: 11602743
  15. Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence.
    J Virol. 2002 Mar;76(5):2518-28 PMID: 11836430
  16. Evaluation in nonhuman primates of vaccines against Ebola virus.
    Emerg Infect Dis. 2002 May;8(5):503-7 PMID: 11996686
  17. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.
    J Virol. 2002 Jun;76(12):6408-12 PMID: 12021376
  18. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans.
    J Virol. 2002 Jul;76(13):6841-4 PMID: 12050398
  19. Evidence against Ebola virus sGP binding to human neutrophils by a specific receptor.
    Virology. 2002 Nov 10;303(1):9-14 PMID: 12482654
  20. DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells.
    Virology. 2003 Jan 5;305(1):115-23 PMID: 12504546
  21. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates.
    Nature. 2003 Aug 7;424(6949):681-4 PMID: 12904795
  22. Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire.
    Lancet. 1977 Mar 12;1(8011):569-71 PMID: 65661
  23. Viral haemorrhagic fever in southern Sudan and northern Zaire. Preliminary studies on the aetiological agent.
    Lancet. 1977 Mar 12;1(8011):571-3 PMID: 65662
  24. The pathology of experimental Ebola virus infection in monkeys.
    J Pathol. 1978 Jul;125(3):131-8 PMID: 102747
  25. Ultrastructural pathology of experimental Ebola haemorrhagic fever virus infection.
    J Pathol. 1985 Nov;147(3):199-209 PMID: 4067737
  26. Preliminary report: isolation of Ebola virus from monkeys imported to USA.
    Lancet. 1990 Mar 3;335(8688):502-5 PMID: 1968529
  27. Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein.
    Virology. 1994 Mar;199(2):469-73 PMID: 8122375
  28. GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases.
    Virology. 1995 Dec 20;214(2):421-30 PMID: 8553543
  29. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages.
    J Virol. 1996 Apr;70(4):2208-14 PMID: 8642644
  30. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing.
    Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3602-7 PMID: 8622982
  31. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses.
    Arch Virol Suppl. 1996;11:135-40 PMID: 8800795
  32. DNA vaccines.
    Annu Rev Immunol. 1997;15:617-48 PMID: 9143702
  33. Immunization for Ebola virus infection.
    Nat Med. 1998 Jan;4(1):37-42 PMID: 9427604
  34. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins.
    Science. 1998 Feb 13;279(5353):1034-7 PMID: 9461435
  35. Gene vaccination: plasmid DNA is more than just a blueprint.
    Immunol Today. 1998 Feb;19(2):89-97 PMID: 9509764
  36. Viral strategies of immune evasion.
    Science. 1998 Apr 10;280(5361):248-53 PMID: 9535648
  37. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.
    Nat Med. 1998 Apr;4(4):397-402 PMID: 9546783
  38. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge.
    Virology. 1998 Jun 20;246(1):134-44 PMID: 9657001
  39. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus.
    J Virol. 1998 Aug;72(8):6442-7 PMID: 9658086
  40. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.
    J Infect Dis. 1998 Sep;178(3):651-61 PMID: 9728532
  41. Ebola virus can be effectively neutralized by antibody produced in natural human infection.
    J Virol. 1999 Jul;73(7):6024-30 PMID: 10364354
  42. Mutational analysis of the putative fusion domain of Ebola virus glycoprotein.
    J Virol. 1999 Oct;73(10):8907-12 PMID: 10482652
  43. Epitopes involved in antibody-mediated protection from Ebola virus.
    Science. 2000 Mar 3;287(5458):1664-6 PMID: 10698744
  44. Ebola haemorrhagic fever--a review.
    J Infect. 2000 Jan;40(1):16-20 PMID: 10762106
  45. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury.
    Nat Med. 2000 Aug;6(8):886-9 PMID: 10932225
  46. Functional importance of the coiled-coil of the Ebola virus glycoprotein.
    J Virol. 2000 Nov;74(21):10194-201 PMID: 11024148
  47. The Ebola virus VP35 protein functions as a type I IFN antagonist.
    Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12289-94 PMID: 11027311
  48. Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry.
    Virology. 2000 Dec 5;278(1):20-6 PMID: 11112476
  49. Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies.
    J Virol. 2001 Feb;75(3):1576-80 PMID: 11152533
  50. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain.
    Mol Cell. 1998 Nov;2(5):605-16 PMID: 9844633
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
DOI
10.1128/jvi.77.18.9733-9737.2003
Published
2003-09-00
Pages
9733-7
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC224575
Subset
IM
External Links
PubMed source DOI: 10.1128/jvi.77.18.9733-9737.2003 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2